Marimed (MRMD) EBIT (2011 - 2026)

Marimed (MRMD) has reported EBIT for 16 consecutive years, with $418000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBIT fell 58.86% year-over-year to $418000.0 in Q2 2026; TTM through Jun 2026 was -$2.4 million, a 13917.65% decrease from a year earlier, with the FY2025 full-year figure at -$2.8 million, down 208.09% from the prior year.
• EBIT was $418000.0 for Q2 2026 at Marimed, up from $125000.0 in the prior quarter.
• Over five years, EBIT peaked at $7.0 million in Q1 2022 and troughed at -$4.5 million in Q4 2025.
• A 5-year average of $2.0 million and a median of $1.8 million in 2024 frame the typical range for EBIT.
• Across the five-year window, EBIT jumped 156.77% in 2022 and tumbled 208.24% in 2025, its largest moves.
• Over 5 years, EBIT stood at $3.1 million in 2022, then dropped by 21.95% to $2.4 million in 2023, then tumbled by 160.89% to -$1.5 million in 2024, then plunged by 208.24% to -$4.5 million in 2025, then soared by 109.24% to $418000.0 in 2026.
• The last three EBIT figures came in at $418000.0 (Q2 2026), $125000.0 (Q1 2026), and -$4.5 million (Q4 2025), per Business Quant data.